Recent research has revealed that PON2 is upregulated in tissues from patients with various types of solid tumors and hematologic cancers, likely due to its ability to suppress oxidative stress and evade apoptosis. Here, PON2 is linked to hematopoietic and lymphoid cell neoplasm.